madman
Super Moderator
The FDA Listened on Estrogen. Is Testosterone Next?
Dr Rachel Rubin and experts Dr Mohit Khera and Dr Abraham Morgentaler discuss a landmark FDA meeting and why it’s time to modernize testosterone therapy labeling and scheduling.
www.medscape.com
Rachel Rubin, MD
Hello, everyone. I’m Dr Rachel Rubin, and we’re here for another episode of Sex Matters. I am thrilled to introduce two of my major mentors. I can’t say enough wonderful things about these two human beings. What I know about advocacy and education has really come from these two men, as well as a few other people.
They did something significant recently and are joining me to talk about it. We went to the FDA earlier this summer to advocate for hormone therapy products for women. On December 10, 2025, experts were invited to the FDA to discuss men’s health and testosterone therapy. We are so excited that advocacy is working; the FDA has asked for the labeling to be changed on estrogen products, and now we are asking for more when it comes to testosterone products.
